Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy

Pediatric Neurology

Volumn 30, Issue 2, 2004, Pages 102-106

  Lazarowski, Alberto ^a,d   Lubieniecki, Fabiana ^b   Camarero, Sandra ^b   Pomata, Hugo ^b   Bartuluchi, Marcelo ^b   Sevlever, Gustavo ^c   Taratuto, Ana Lía ^b,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^d Inst Invest Neurologicas Dr R ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; ASTROCYTE; BRAIN BLOOD VESSEL; BRAIN CORTEX; CONTROLLED STUDY; DYSPLASIA; EPILEPTIC FOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROGLIA; NERVE CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEIZURE; SURGICAL TECHNIQUE; TUBEROUS SCLEROSIS;

EID: 1342345254     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(03)00407-7     Document Type: Article

References (42)

1. van Slegtenhorst M., Nellist M., Nagelkerken B., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet. 7:1998;1053-1057.
2. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
3. Jin F., Wienecke R., Xiao G.H., Maize J.C. Jr, DeClue J.E., Yeung R.S. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA. 93:1996;9154-9159.
4. Orimoto K., Tsuchiya H., Kobayashi T., Matsuda T., Hino O. Suppression of the neoplastic phenotype by replacement of the Tsc2 gene in Eker rat renal carcinoma cells. Biochem Biophys Res Commun. 219:1996;70-75.
5. Bush J.A., Li G. Cancer chemoresistance The relationship between p53 and multidrug transporters . Int J Cancer. 98:2002;323-330.
6. Juliano R.L., Ling V.A. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta. 445:1976;152-162.
7. Gottesman M.M., Pastan I. The multidrug transporter, a double-edge sword. J Biol Chem. 263:1988;12163-12166.
8. Cole S.P., Deeley R.G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 20:1998;931-940. [Review].
9. McClintock WM. Neurologic manifestations of tuberous sclerosis complex. Curr Neurol Neurosci Rep 2002;158-63 [Review].
10. Curatolo P., Verdecchia M., Bombardieri R. Tuberous sclerosis complex A review of neurological aspects . Eur J Paediatr Neurol. 6:2002;15-23.
11. Avellino A.M., Berger M.S., Rostomily R.C., Shaw C.M., Ojemann G.A. Surgical management and seizure outcome in patients with tuberous sclerosis. J Neurosurg. 87:1997;391-396.
12. Crino P.B., Miyata H., Vinters H.V. Neurodevelopmental disorders as a cause of seizures Neuropathologic, genetic, and mechanistic considerations . Brain Pathol. 12:2002;212-233.
13. Lazarowski A., Sevlever G., Taratuto A., Massaro M., Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Ped Neurol. 21:1999;731-734.
14. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., Thom M. Drug resistance in epilepsy Expression of drug resistance proteins in common cause of refractory epilepsy . Brain. 125:2002;22-31.
15. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 36:1995;1-6.
16. Zhang L., Ong W., Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injection. Exp Brain Res. 126:1999;509-516.
17. Lazarowski A., Girardi E., Ramos A., García-Rivello H., Brusco A. MDR-1 gene expression (Pgp-170) in different brain areas in an experimental epilepsy model [Abstract]. J Epilepsy Clin Neurophysiol. 8:2002;101.
18. Seegers U., Potschka H., Löscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia. 43:2002;675-684.
19. Rizzi M., Caccia S., Guisso G., et al. Limbic seizures induce P-glycoprotein in rodent brain Functional implications for pharmacoresistance . J Neurosci. 22:2002;5833-5839.
20. Kwan P., Sills G.J., Butler E., Gant T.W., Meldrum B.S., Brodie M.J. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia. 43:2002;1318-1323.
21. Lazarowski A., Girardi E., Ramos A.J., García-Rivello H., Brusco A. Neuronal MDR-1 gene encoded P-glycoprotein (P-170) expression in 3-mercaptopropionic acid-induced seizures in rats. Epilepsia. 43:(Suppl. 7):2002;11-12.
22. Sullivan G.F., Yang J.M., Vassil A., Yang J., Bash-Babula J., Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest. 105:2000;1261-1267.
23. Fukushima Y., Oshika Y., Tokunaga T., et al. Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer. Eur J Cancer. 35:1999;935-938.
24. Oka M., Kounoura K., Narasaki F., et al. P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res. 88:1997;738-742.
25. Thottassery J.V., Zambetti G.P., Arimori K., Schuetz E.G., Schuetz J.D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 94:1997;11037-11042.
26. Linn S.C., Honkoop A.H., Hoekman K., van der Valk P., Pinedo H.M., Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer. 74:1996;63-68.
27. Ralhan R., Swain R.K., Agarwal S., et al. P-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosis. Int J Cancer. 84:1999;80-85.
28. Sampath J., Sun D., Kidd V.J., et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem. 276:2001;39359-39367.
29. Zhan M., Yu D., Lang A., Li L., Pollock R.E. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer. 92:2001;1556-1566.
30. Kawaguchi K., Oda Y., Nakanishi K., et al. Malignant transformation of renal angiomyolipoma A case report . Am J Surg Pathol. 26:2002;523-529.
31. Kim S.K., Wang K.C., Cho B.K., et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol. 52:2001;217-225.
32. Lantuejoul S., Ferretti G., Negoescu A., Parent B., Brambilla E. Multifocal alveolar hyperplasia associated with lymphangioleiomyomatosis in tuberous sclerosis. Histopathology. 30:1997;570-575.
33. Cocker H.A., Pinkerton C.R., Kelland L.R. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell line. Br J Cancer. 83:2000;338-345.
34. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:2002;5645-5650.
35. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA. 99:2002;13571-13576.
36. Onda H., Crino P.B., Zhang H., et al. Tsc2 Null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci. 21:2002;561-574.
37. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62:2002;6141-6145.
38. Hudson C., Liu M., Chiang G., et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol. 22:2002;7004-7014.
39. Semenza G. HIF-1 and tumor progression Pathophysiology and therapeutics . Trends Mol Med. 8:(Suppl. 4):2002;S62-67. [Review].
40. Comerford K., Wallace T., Karhausen J., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:2002;3387-3394.
41. Sacyshyn B.R., Bowen-Yacyshyn M.B., Pilasky L.M. Inhibition by rapamycyn of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol. 43:1996;449-455.
42. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic drugs. 4th ed:1995;Raven Press, New York.